List of Genedata Biopharma Platform Customers
Genedata
Margarethenstrasse 38,
Basel, 4053,
Switzerland
Basel, 4053,
Switzerland
41 61 511 84 00
Professional Services
400
$45M
Since 2010, our global team of researchers has been studying Genedata Biopharma Platform customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Genedata Biopharma Platform for Life Science R&D Platforms from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Genedata Biopharma Platform for Life Science R&D Platforms include: Roche, a Switzerland based Life Sciences organisation with 112774 employees and revenues of $80.28 billion, AstraZeneca, a United Kingdom based Life Sciences organisation with 94300 employees and revenues of $73.98 billion, Merck, a United States based Life Sciences organisation with 73000 employees and revenues of $64.17 billion, Pfizer, a United States based Life Sciences organisation with 81000 employees and revenues of $63.63 billion, Bayer, a Germany based Life Sciences organisation with 92815 employees and revenues of $55.47 billion and many others.
Contact us if you need a completed and verified list of companies using Genedata Biopharma Platform, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Genedata Biopharma Platform customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Agenus | Life Sciences | 400 | $161M | United States | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2018 | n/a |
In 2018, Agenus implemented Genedata Biopharma Platform to consolidate antibody discovery workflows and support its immuno-oncology and vaccine R&D programs. The Genedata Biopharma Platform was deployed as an end-to-end Life Science R&D Platforms solution to standardize data capture and workflow management across research activities and to provide a single backbone for discovery-through-selection processes across the company.
The implementation configured modules for screening, engineering, expression, purification, and analytics for large-molecule and antibody workflows, including support for bispecifics and next-generation molecule types. Molecule, sample, assay, and analytics data flows were instrumented to capture developability and manufacturability attributes alongside experimental results, aligning platform capabilities with antibody discovery and candidate progression processes.
Genedata Biopharma Platform was integrated into Agenus’s broader data ecosystem, explicitly linking with the company’s Intelligent Re search AIR platform to enable shared access to large-molecule R&D data. Data and information were federated between project teams and research sites in the US and the UK, enabling cross-site collaboration and centralized access to assay and analytics outputs.
Governance and operational workflows were restructured to use the Genedata Biopharma Platform as the authoritative source for therapeutic candidate evaluation, enabling systematic and transparent decision-making when selecting candidates for clinical progression. The platform augmented Agenus scientists’ ability to capture, process, and interpret complex biologics data and served as a core component of the company’s collaborative data and information platform.
|
 |
Amgen | Life Sciences | 28000 | $33.4B | United States | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2018 | n/a |
In 2018 Amgen implemented Genedata Biopharma Platform to support a new workflow for development of bispecific antibody therapeutics, targeting high-throughput binding and large molecule assay analysis. The deployment centered on discovery scientists analyzing high-volume assay outputs to accelerate candidate selection, and it is positioned within the Life Science R&D Platforms category to support research informatics needs.
The implementation relied on Genedata Screener as the analytic engine of the Genedata Biopharma Platform, applying automated analysis of high-volume data, automated fitting, and result derivation. Built-in business logic and pre-defined processing parameters were configured to standardize curve fitting, endpoint calculation, and result flagging, enabling repeatable, auditable processing of large molecule assay data.
Operational integration included reliable reporting pipelines to Amgen's data warehouse and generation of reports containing key result values and raw data traces for downstream review. Governance and process change emphasized consistent analysis through parameterized workflows and automated result derivation, and the initiative explicitly enabled rapid identification of rare bispecific molecules with promising properties, consistent analysis across experiments, and easier sharing of results via warehouse reporting.
|
 |
AstraZeneca | Life Sciences | 94300 | $74.0B | United Kingdom | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2019 | n/a |
In 2019, AstraZeneca deployed the Genedata Biopharma Platform to automate mass spectrometry based high throughput screening data processing for Discovery Sciences in Cambridge, UK. The Genedata Biopharma Platform was implemented as a Life Science R&D Platforms solution to support Acoustic Mist Ionization Mass Spectrometry AMI MS workflows and centralize MS data handling for mechanistic biology and profiling teams.
Deployment centered on Genedata Expressionist as the primary processing module, configured with automated, customizable workflows that parse raw AMI MS files and assign spectra to individual wells from multi 384 well plate runs. Key capabilities implemented include dynamic peak detection and clustering algorithms, metadata driven automated processing, spectrum quality filtering, and configurable export pipelines, enabling single click processing of complex AMI MS data sets.
Integration workstreams routed processed results into the existing Genedata Screener analysis platform, with each AMI MS file automatically uploaded and processed using predefined workflows before seamless export to Screener for plate wise visualization and QC. The implementation explicitly supports AMI MS instrument output and high throughput screening pipelines, processing example data sets of 150 times 384 well plates within an automated end to end flow.
Governance was enforced through user definable settings and lockable workflows, enabling reproducible, auditable processing across laboratories and facilitating shared workflow templates for assay development. Detailed visualization and inspection at every processing stage were configured to support assay optimization, triage of false positives, and traceable data review practices.
Measured outcomes reported by AstraZeneca include a seven fold decrease in processing time with elimination of potentially error inducing manual interactions, with a representative workflow reducing processing from approximately three hours to around 25 minutes for large plate sets. The solution preserved flexibility to handle data from any mass spectrometer and to accommodate multiple assay strategies, while improving consistency and traceability of HTS MS data.
|
 |
Bayer | Life Sciences | 92815 | $55.5B | Germany | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2018 | n/a |
In 2018, Bayer extended its long-term partnership with Genedata, licensing Genedata Selector and advancing deployment of the Genedata Biopharma Platform as part of its Life Science R&D Platforms strategy to digitalize Crop Science research and discovery. The engagement centers on Bayer Crop Science R&D and explicitly targets global discovery process and data management for the development of new fungicides, with Bayer scientists in Monheim, Germany and worldwide provided centralized data access.
The implementation focuses on enterprise scale bioinformatics capabilities, including processing, storing, analysis and evaluation of genomic data derived from NGS, microarray and other high throughput omics technologies. Genedata Selector is described as the entry point to harmonize heterogeneous information such as genome sequences, assemblies and gene models, and to consolidate experiment, breeding and chemical screening data into a single, scalable, integrated and secure platform for end to end data management and analysis.
Operationally the platform was positioned to provide global data access to interdisciplinary teams and to streamline discovery workflows by enabling collaboration and communication across fields, farms and laboratories. Governance emphasis in the announcement highlights data harmonization and a centralized access model as the mechanism to organize large volumes of crop related data, a capability Bayer framed as essential to its Crop Science R&D processes and captured in Bayer statements comparing the platform to a structured library for rapid retrieval and analysis.
|
 |
Bristol Myers Squibb | Life Sciences | 34100 | $48.3B | United States | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2022 | n/a |
In 2022, Bristol Myers Squibb deployed the Genedata Biopharma Platform to centralize biotherapeutics screening and assay data across its discovery organization, using the Life Science R&D Platforms category to structure the program. The initiative addressed a fragmented environment where multiple systems of record and divergent processes per site made it difficult for scientists to compile data packages for candidate selection and AI ML workflows.
The Genedata Biopharma Platform was configured to provide a single data capture experience and consistent workflows across discovery biotherapeutics sites, standardizing assay metadata, screening results, and quality control annotations. Configuration emphasized an AI ML ready data model and validation rules to improve data consistency, with functional capabilities aligned to the needs of biotherapeutics candidate selection and molecular comparison across groups.
Operational coverage focused on discovery biotherapeutics sites and the scientist user community responsible for candidate selection and in silico prediction, consolidating inputs that had previously been distributed across multiple systems of record. The deployment created a centralized source of curated assay and screening data to support cross-platform molecule comparison and downstream machine learning pipelines.
Governance changes centered on workflow standardization and a single capture policy, enabling consistent data capture practices across sites and clearer decision package assembly for selection reviews. The program is described by Bristol Myers Squibb as simplifying the biotherapeutics data ecosystem and providing a single data capture experience to support AI ML enabled research.
|
 |
|
Life Sciences | 60 | $15M | United Kingdom | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2018 | n/a |
|
|
|
|
Life Sciences | 6000 | $2.3B | Switzerland | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2020 | n/a |
|
|
|
|
Life Sciences | 2635 | $2.3B | Denmark | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2020 | n/a |
|
|
|
|
Life Sciences | 150 | $131M | United States | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2020 | n/a |
|
|
|
|
Life Sciences | 73000 | $64.2B | United States | Genedata | Genedata Biopharma Platform | Life Science R&D Platforms | 2019 | n/a |
|
Showing 1 to 10 of 16 entries
Buyer Intent: Companies Evaluating Genedata Biopharma Platform
ARTW Buyer Intent uncovers actionable customer signals, identifying software buyers actively evaluating Genedata Biopharma Platform. Gain ongoing access to real-time prospects and uncover hidden opportunities. Companies Actively Evaluating Genedata Biopharma Platform for Life Science R&D Platforms include:
- Shimadzu, a Japan based Healthcare organization with 14219 Employees
- Irusri Sweden, a Sweden based Professional Services company with 10 Employees
- University at Buffalo, a United States based Education organization with 6037 Employees
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||
FAQ - APPS RUN THE WORLD Genedata Biopharma Platform Coverage
Genedata Biopharma Platform is a Life Science R&D Platforms solution from Genedata.
Companies worldwide use Genedata Biopharma Platform, from small firms to large enterprises across 21+ industries.
Organizations such as Roche, AstraZeneca, Merck, Pfizer and Bayer are recorded users of
Genedata Biopharma Platform for Life Science R&D Platforms.
Companies using Genedata Biopharma Platform are most concentrated in Life Sciences, with adoption spanning over 21 industries.
Companies using Genedata Biopharma Platform are most concentrated in Switzerland, United Kingdom and United States, with adoption tracked across 195 countries worldwide. This global distribution highlights the popularity of Genedata Biopharma Platform across Americas, EMEA, and APAC.
Companies using Genedata Biopharma Platform range from small businesses with 0-100 employees - 6.25%, to mid-sized firms with 101-1,000 employees - 18.75%, large organizations with 1,001-10,000 employees - 18.75%, and global enterprises with 10,000+ employees - 56.25%.
Customers of Genedata Biopharma Platform include firms across all revenue levels — from $0-100M, to $101M-$1B, $1B-$10B, and $10B+ global corporations.
Contact APPS RUN THE WORLD to access the full verified Genedata Biopharma Platform customer database with detailed Firmographics such as industry, geography, revenue, and employee breakdowns as well as key decision makers in charge of Life Science R&D Platforms.